Eiger BioPharmaceutics: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Eiger BioPharmaceutics listata cu simbolul US.EIGR ==Descriere companie== Eiger BioPharmaceuticals, Inc. (www.eigerbio.com) is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of drugs for serious diseases. Its lead clinical programs are focused on the development of treatments for Hepatitis Delta Virus (HDV), the severe form of viral hepatitis. Its clinical product candidates include Lona...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Eiger BioPharmaceuticals, Inc. (www.eigerbio.com) is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of drugs for serious diseases. Its lead clinical programs are focused on the development of treatments for Hepatitis Delta Virus (HDV), the severe form of viral hepatitis. Its clinical product candidates include Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). LNF is an orally bioavailable, farnesylation inhibitor in a Phase III clinical trial for HDV infection. Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing for the treatment for PBH. Avexitide is for the treatment of congenital hyperinsulinism (CHI), pediatric metabolic disorder. | Eiger BioPharmaceuticals, Inc. (www.eigerbio.com) is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of drugs for serious diseases. Its lead clinical programs are focused on the development of treatments for Hepatitis [[DELTA|Delta]] Virus (HDV), the severe form of viral hepatitis. Its clinical product candidates include Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). LNF is an orally bioavailable, farnesylation inhibitor in a Phase III clinical trial for HDV infection. Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing for the treatment for PBH. Avexitide is for the treatment of congenital hyperinsulinism (CHI), pediatric metabolic disorder. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 30 septembrie 2024 15:51
Pagina dedicata companiei Eiger BioPharmaceutics listata cu simbolul US.EIGR
Descriere companie[edit | ]
Eiger BioPharmaceuticals, Inc. (www.eigerbio.com) is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of drugs for serious diseases. Its lead clinical programs are focused on the development of treatments for Hepatitis Delta Virus (HDV), the severe form of viral hepatitis. Its clinical product candidates include Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). LNF is an orally bioavailable, farnesylation inhibitor in a Phase III clinical trial for HDV infection. Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing for the treatment for PBH. Avexitide is for the treatment of congenital hyperinsulinism (CHI), pediatric metabolic disorder.
Grafic actiuni companie[edit | ]